Replies to post #222104 on Biotech Values

[dewophile]

I’m not in a position to judge this point any more than any other lay person. I will say though that majority of melanoma (unlike most other cancers) is treated in academic centers versus community. I’ve also seen other trials where there were differences in outcomes that were felt to be due to experience and management of AEs

[DewDiligence]

Re: “Community” vs “academic” management of AEs

Did you make anything of Dr. Diab's comments about academic centers managing AE's better and getting higher responses or is that a generalization that can be applied to most new immuno-oncology therapies?

This is true for oncology in general, in my experience.

Dr. Diab gave a practical explanation for the disparity: “community” oncologists have to go out of their way, literally, to treat hospitalized patients; academic oncologists, on the other hand, are working in a hospital setting all the time, and hence managing AEs for hospitalized patients is not unduly burdensome.